<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1571">
  <stage>Registered</stage>
  <submitdate>22/12/2003</submitdate>
  <approvaldate>22/12/2003</approvaldate>
  <actrnumber>ACTRN12606000526572</actrnumber>
  <trial_identification>
    <studytitle>Advanced oesophageal cancer study to compare quality of life and palliation of dysphagia</studytitle>
    <scientifictitle>Trans Tasman Radiation Oncology Group (TROG) 03.01 - A randomised phase III study in advanced oesophageal cancer to compare quality of life and palliation of dysphagia in patients treated with radiotherapy versus chemo-radiotherapy (cisplatin &amp; 5-Flurouracil).</scientifictitle>
    <utrn />
    <trialacronym>TROG 03.01</trialacronym>
    <secondaryid>clinicalTrials.gov ID NCT00193882</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Advanced oesophagus cancer, not suitable for radical treatment.</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Oesophageal (gullet)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Arm 2: Chemo-radiotherapy. 35Gy in 15 fractions (Overall, treatment time will not exceed 25 days total for the 3 week course and 18 days for the 2 week course of radiation)  plus Cisplatin 80mg/m squared IV day 1 (or 20mg/m sqaured/day IV each day from 1-4 only one cycle) plus 5-Fluorouacil 800mg/m squared/day IV days 1-4 (radiotherapy and chemotherapy are simultaneous)</interventions>
    <comparator>Arm 1: Radiotherapy alone. 35 Gy in 15 fractions. Overall, treatment time will not exceed 25 days total for the 3 week course and 18 days for the 2 week course of radiation. </comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Relief of dysphagia. Defined as improvment of at least one point on the Mellow scale. </outcome>
      <timepoint>This will be measured at nine weeks after the start of radiotherapy and must be maintained at the next review 4 weeks thereafter.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>1. Dysphagia progression free survival.</outcome>
      <timepoint>Measured from randomisation to the time of first progression of dysphagia. Progression will be defined as a drop of at least one point on the scale or stricture requiring intervention or death. Measured weeks 5 &amp; 9 after the start of treatment, every month until one year post randomisation, then 3 monthly for two years and then yearly until death (all patients).     </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>2. Time to achieve any response in dysphagia.</outcome>
      <timepoint>Measured weeks 5 &amp; 9 after the start of treatment, every month until one year post randomisation, then 3 monthly for two years and then yearly until death (all patients).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>3. Quality of Life</outcome>
      <timepoint>Differences post treatment (at the end of the treatment cycles) and at monthly intervals for the first 12 months and then 3 monthly until death (all patients). </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>4. Acute and late toxicity. </outcome>
      <timepoint> Measured weeks 5 &amp; 9 after the start of treatment, every month until one year post randomisation, then 3 monthly for two years and then yearly until death (all patients).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>5. Survival.</outcome>
      <timepoint>All patients followed until death.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Biopsy proven carcinoma of the Oesophagus
2. Not a candidate for radical/curative treatment due to the advanced nature of the disease, presence of metastases, or intercurrent illness (it should be noted that, patients with mediastinal nodes and no more distant disease maybe suitable for radical treatment).
3. Symptomatic patients with dysphagia scores of =&gt; 1 i.e. able to eat only some sollids (see appendix 1) 
4. Performance status Eastern Cooperative Oncology Group (ECOG) less than or equal to 2
5. Patients msut begin treatment within 2 weeks of randomisation
6. Patient is at least 18 years old 
7. Adequate haematology function to undergo chemotherapy Peripheral blood - Neutrophils &gt; 1.5 x 109/L - Platelets &gt; 100 x 109/L
8. Adequate renal function, Creatine - Calculated clearence 50 ml/min (see appendix 1).
9. Patients capable of child bearing are using adequate contraception. 
10. Written informed consent of patient.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Previous mega-voltage external beam Radiotherapy or brachy-therapy delivered to the region of the chest. 
2. Synchronous active malignancies. 
3. Pregnant or lactating patients. 
4. Patients unfit for any treatment component. 
5. Tracheo-oesophageal fistula. 
6. Stents in situ.
7. Previous chemotherapy for Oesophageal Cancer
8. CT scan of thorax and abdomen more than 8 weeks prior to randomisation
9. Full Blood Count, Biochemistry (including creatinine) and creatinine clearance more than 2 weeks prior to randomisation
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation</concealment>
    <sequence>Stratified allocation. Factors: Presence of Metastases, Dysphagia score, Insititution. Simple randomisation by computer.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>7/07/2003</anticipatedstartdate>
    <actualstartdate>7/07/2003</actualstartdate>
    <anticipatedenddate />
    <actualenddate>20/03/2012</actualenddate>
    <samplesize>220</samplesize>
    <actualsamplesize>220</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>20/03/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia,Outside</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,WA,VIC</recruitmentstate>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>Trans Tasman Radiation Oncology Group  </primarysponsorname>
    <primarysponsoraddress>TROG Central Operations Office
Calvary Mater Newcastle 
MHAB Level 5
Edith Street 
Waratah, NSW
2310</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health &amp; Medical Research Council</fundingname>
      <fundingaddress>Level 5, 20 Allara St Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Cancer Council Tasmania</fundingname>
      <fundingaddress>Level 5, 20 Allara St Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Cancer Institute of Canada</fundingname>
      <fundingaddress>10 Alcorn Avenue, Suite 200 Toronto, Ontario M4V 3B1</fundingaddress>
      <fundingcountry>Canada</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other</sponsortype>
      <sponsorname>National Cancer Institute of Canada (NCIC)</sponsorname>
      <sponsoraddress>10 Alcorn Avenue, Suite 200 Toronto, Ontario M4V 3B1</sponsoraddress>
      <sponsorcountry>Canada</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>People with cancer of the oesophagus (gullet) often have trouble swallowing.  Radiotherapy can help improve this problem.  Using chemotherapy together with radiotherapy may work better but has more side effects.  This trial will determine if it is better to use radiotherapy by itself or together with chemotherapy.</summary>
    <trialwebsite />
    <publication>Abstract 66:  Penniment M. A randomized phase III study in advanced esophageal cancer (OC) to compare the quality of life (QoL) and palliation of dysphagia in patients treated with radiotherapy (RT) or chemoradiotherapy (CRT) TROG 03.01 NCIC CTG ES.2. ASCO May 30-June 2, Chicago Illinois. Poster presentation.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>AHSC St John Regional Health</ethicname>
      <ethicaddress />
      <ethicapprovaldate>1/11/1999</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Canada</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Box Hill Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Cancer Care Manitoba</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Canada</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Christchurch Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Cross Cancer Institute</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Canada</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Geelong Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Grand River Regional Cancer Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Canada</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Hotel-Dieu de Quebec</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Canada</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Kingston Regional Cancer centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Canada</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Liverpool Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Mater QRI</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Nova Scotia Cancer centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Canada</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Peter MacCallum Cancer Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Princess Alexandra Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Prince of Wales Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Princess Margaret Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Canada</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Queen Elizabeth Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Perth Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Michael Penniment</name>
      <address>Royal Adelaide Hospital
Radiation Oncology
North Terrace ADELAIDE SA 5000</address>
      <phone>+61 8 8222 4000</phone>
      <fax />
      <email>mpennime@mail.rah.sa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Sonya Stephens</name>
      <address>Royal Adelaide Hospital
Radiation Oncology
North Terrace
Adelaide SA 5000</address>
      <phone>+61 8 8222 4042</phone>
      <fax />
      <email>sonya.stephens@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>TROG Administrator</name>
      <address>TROG Cancer Research
PO Box 88
Waratah NSW 2298</address>
      <phone>+61 2 4014 3910  </phone>
      <fax>+61 2 4014 3902</fax>
      <email>administrator@trog.com.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Michael Penniment  </name>
      <address>Royal Adelaide Hospital
North Terrace
Adelaide SA, 5000</address>
      <phone>+61 8 8222 4000  </phone>
      <fax />
      <email>mpennime@mail.rah.sa.gov.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>